Pharma visual inspection
Visual-inspection AI for pharmaceutical manufacturing
Evaluate a clearly defined inspection task for tablets, vials, ampoules or packaging. NeoBram scopes the imaging conditions, defect evidence and review workflow with your quality specialists before making a claim about suitability.
Specify what is being inspected
Start with one product presentation, inspection station and defined defect taxonomy. Tablet surface defects, vial particulates and packaging-code checks are different tasks with different evidence requirements. State whether the proposed system supports an inspector, sorts candidates for review or is being assessed for another intended use. The quality unit approves that boundary.
Check the image before selecting a model
Assess optics, lighting, container material, product movement, line rate and the visibility of the relevant defect. Preserve lot, product and capture context where authorized. A defect that is not reliably visible in the available image cannot be recovered by a confident model output.
- Build a quality-reviewed defect library with known classes, borderline examples and acceptable product variation.
- Include rare or difficult conditions explicitly and record gaps in available examples rather than assuming broad coverage.
- Record camera configuration, image quality, line conditions and source identity so evaluation findings can be traced to a defined setup.
Design the review and disposition process
Define how an inspection result is linked to the relevant item or batch and shown to a qualified reviewer. Ambiguous cases need an agreed disposition, including fallback when the camera or model is unavailable. Any reject mechanism, line interface or batch-record connection requires separate engineering and quality review. A software demonstration does not validate a production inspection process.
Test false acceptance and false rejection
Agree the reference inspection method, sampling approach and acceptance criteria with quality specialists. Evaluate held-out lots and representative operating conditions, reporting false accepts and false rejects by defect class. Avoid near-duplicate images across training and evaluation. Test presentation changes, lighting drift, line-rate limits and unknown defects; one overall accuracy percentage can conceal a critical miss.
Keep validation tied to intended use
Document the proposed system boundary, data and model versions, test evidence, user roles and controlled-change process. Validation deliverables and responsibilities must be explicitly scoped with the customer’s qualified owners. This page does not establish GxP suitability, electronic-record compliance or regulatory acceptance. Applicable requirements depend on the implemented workflow and the evidence reviewed by the quality unit.
Agree the inspection evidence package
A scoped engagement may produce an imaging-feasibility review, defect definitions, evaluated prototype, class-level results and a record of limitations. Handover identifies configuration ownership, retained evidence, monitoring and change triggers. Model updates, new product presentations or modified inspection hardware need a reviewed decision about re-evaluation; they must not enter use through unapproved automatic retraining.
An illustrative blister inspection trial
A team evaluates missing-tablet detection on one blister format. Reviewers label representative images, including reflections and acceptable product variation, then assess errors on separate production lots. Borderline results follow the agreed inspection procedure. This example describes a possible evaluation; it is not evidence of validated release inspection, a detection rate or regulatory approval.
Bring the defect specification and quality owner
Start with the inspection requirement, representative product samples and the present disposition process. Confirm access to suitable images and an authoritative reference before choosing hardware or models. The next decision is whether a controlled evaluation is justified. Product release, investigation closure and approval of the inspection process remain with authorized quality personnel.
More clarity
Questions and answers
Can AI be the sole basis for product release?
That is outside an initial feasibility or advisory scope. Any release-related intended use needs the customer’s qualified validation and quality approval, with appropriate evidence for the actual process.
How many defect images are required?
There is no universal number. It depends on defect variability, presentation, criticality and the reference method. Rare defects and missing conditions must be identified as evidence gaps.
Does a validated tablet model cover vials or ampoules?
No. Different products, defects, optics and presentation conditions require their own scope and evaluation. Results must not be transferred without supporting evidence.
Are MES and QMS integrations included automatically?
No. Interfaces, permissions, record identity, failure behavior and quality responsibilities must be specified and tested. Mentioning an existing system does not establish compatibility.
What happens after a model or camera change?
The defined change-control process determines the impact assessment and re-evaluation required. Responsible technical and quality owners approve release of the changed configuration.
Start with one business problem